Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial

BACKGROUND: Pancreatic ductal adenocarcinomas (PDAC) are characterized by frequent cell cycle pathways aberrations. This study evaluated safety and efficacy of abemaciclib, a cyclin‐dependent kinase 4 and 6 inhibitor, as monotherapy or in combination with PI3K/mTOR dual inhibitor LY3023414 or TGFβ i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiorean, E. Gabriela, Picozzi, Vincent, Li, Chung‐Pin, Peeters, Marc, Maurel, Joan, Singh, Jaswinder, Golan, Talia, Blanc, Jean‐Frédéric, Chapman, Sonya C., Hussain, Anwar M., Johnston, Erica L., Hochster, Howard S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLE
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652308/
https://www.ncbi.nlm.nih.gov/pubmed/37840530
http://dx.doi.org/10.1002/cam4.6621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652308/
https://www.ncbi.nlm.nih.gov/pubmed/37840530
http://dx.doi.org/10.1002/cam4.6621

Ejemplares similares